Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:50 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
by Kinjel Shah
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -34.62% and 2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
by Zacks Equity Research
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
Amicus Progresses on Pipeline Development Amid Competition
by Zacks Equity Research
Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amicus Therapeutics, Inc. (FOLD).
How to Find Cheap Buy-Ranked Stocks Trading Under $10
by Benjamin Rains
Check out 5 stocks of the roughly 40 highly-ranked 'cheap' stocks trading under $10 a share that made it through today's screen...
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
by Zacks Equity Research
Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Company News For Nov 12, 2019
by Zacks Equity Research
Companies In The News Are: QRTEA, FOLD, NKTR, WBA, KKR.
Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
by Zacks Equity Research
Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
PCTEL (PCTI) Gears Up for Q3 Earnings: What's in Store?
by Zacks Equity Research
PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.